Thyroid nodule classification: Difference between revisions
Line 2: | Line 2: | ||
{{Thyroid nodule}} | {{Thyroid nodule}} | ||
{{CMG}}; {{AE}} {{MIR}} | {{CMG}}; {{AE}} {{MIR}} | ||
== Overview == | |||
== Classification == | |||
Differentiated and anaplastic thyroid carcinoma TNM staging AJCC UICC 2017 | |||
Bethesda System for Reporting Thyroid Cytopathology | |||
Thyroid nodule classification based on TIRAD sonographhic features | |||
==== Bethesda System for Reporting Thyroid Cytopathology ==== | ==== Bethesda System for Reporting Thyroid Cytopathology ==== | ||
<ref name="pmid19888858">{{cite journal |vauthors=Cibas ES, Ali SZ |title=The Bethesda System for Reporting Thyroid Cytopathology |journal=Thyroid |volume=19 |issue=11 |pages=1159–65 |year=2009 |pmid=19888858 |doi=10.1089/thy.2009.0274 |url=}}</ref> | <ref name="pmid19888858">{{cite journal |vauthors=Cibas ES, Ali SZ |title=The Bethesda System for Reporting Thyroid Cytopathology |journal=Thyroid |volume=19 |issue=11 |pages=1159–65 |year=2009 |pmid=19888858 |doi=10.1089/thy.2009.0274 |url=}}</ref> |
Revision as of 20:30, 28 August 2017
Thyroid nodule Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Thyroid nodule classification On the Web |
American Roentgen Ray Society Images of Thyroid nodule classification |
Risk calculators and risk factors for Thyroid nodule classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]
Overview
Classification
Differentiated and anaplastic thyroid carcinoma TNM staging AJCC UICC 2017
Bethesda System for Reporting Thyroid Cytopathology
Thyroid nodule classification based on TIRAD sonographhic features
Bethesda System for Reporting Thyroid Cytopathology
classification | FNA cytology | Predicted risk of malignancy |
---|---|---|
Benign |
|
0–3 % |
Nondiagnostic or Unsatisfactory | 1–4 % | |
Follicular lesion of undetermined significance |
|
5–15 % |
Atypia of undetermined significance |
| |
Follicular neoplasm |
|
15–30 % |
Suspicious for a follicular neoplasm |
|
60–75 % |
Malignant |
|
97–99 % |
Classification of neoplastic thyroid nodules based on their origin:
Origin | histologic subtypes | Subclass | ||
---|---|---|---|---|
Nonmedullary thyroid cancers (NMTCs) | 95% of tumors | thyroid epithelial cells | papillary (85%) | 95% are sporadic tumors
5% may be related to inherited genetics due to familial origin
|
follicular (11%) |
| |||
Hürthle cell (3%) | ||||
anaplastic (1%) | ||||
Medullary thyroid cancers (MTCs) | 5% of all thyroid malignancies | calcitonin-producing parafollicular cells | 20% they are familial and occur as part of the multiple endocrine neoplasia (MEN) syndromes |
Of the differentiated cancers, papillary cancer comprises about 85% of cases compared to about 10% that have follicular histology, and 3% that are Hu¨rthle cell or oxyphil tumors
Thyroid nodule classification based on the sonographhic features:
Classification system has been proposed by Horvath et al, with a modified recommendation from Jin Kwak et al.[2]
TIRADS 1 | Normal thyroid gland | |||
TIRADS 2 | Benign lesions |
|
0% risk of malignancy | |
TIRADS 3 | Probably benign lesions |
|
<5% risk of malignancy | |
TIRADS 4 | 4a | One suspicious feature |
|
5-10% risk of malignancy |
4b | Two suspicious features | 10-80% risk of malignancy | ||
4c | Three/four suspicious features | |||
TIRADS 5 | All five suspicious features | Probably malignant lesions (more than 80% risk of malignancy) | >80% risk of malignancy | |
TIRADS 6 | Biopsy proven malignancy |
Classification based on TNM
Differentiated and anaplastic thyroid carcinoma TNM staging AJCC UICC 2017
Papillary, follicular, poorly differentiated, Hurthle cell and anaplastic thyroid carcinoma | ||||||||
Primary tumor (T) | Regional lymph nodes (N) | Distant metastasis (M) | ||||||
T category | T criteria | N category | N criteria | M category | M criteria | |||
TX | Primary tumor cannot be assessed | NX | Regional lymph nodes cannot be assessed | M0 | No distant metastasis | |||
T0 | No evidence of primary tumor | N0 | No evidence of locoregional lymph node metastasis | M1 | Distant metastasis | |||
T1 | Tumor ≤2 cm in greatest dimension limited to the thyroid | N0a | One or more cytologically or histologically confirmed benign lymph nodes | |||||
T1a | Tumor ≤1 cm in greatest dimension limited to the thyroid | N0b | No radiologic or clinical evidence of locoregional lymph node metastasis | |||||
T1b | Tumor >1 cm but ≤2 cm in greatest dimension limited to the thyroid | N1 | Metastasis to regional nodes | |||||
T2 | Tumor >2 cm but ≤4 cm in greatest dimension limited to the thyroid | N1a | Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. | |||||
T3 | Tumor >4 cm limited to the thyroid, or gross extrathyroidal extension invading only strap muscles | N1b | Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes | |||||
T3a | Tumor >4 cm limited to the thyroid | |||||||
T3b | Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size | |||||||
T4 | Includes gross extrathyroidal extension | |||||||
T4a | Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size | |||||||
T4b | Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size |
References
- ↑ Cibas ES, Ali SZ (2009). "The Bethesda System for Reporting Thyroid Cytopathology". Thyroid. 19 (11): 1159–65. doi:10.1089/thy.2009.0274. PMID 19888858.
- ↑ Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, Dominguez M (2009). "An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management". J. Clin. Endocrinol. Metab. 94 (5): 1748–51. doi:10.1210/jc.2008-1724. PMID 19276237.